Recombinant MVA vaccines: dispelling the myths

Highlights • Recombinant MVA is most immunogenic as a heterologous boost after strong priming. • Most transgenes do not result in genetic instability of recombinant MVA. • Large-scale manufacturing of non-recombinant MVA is a reality. • Anti-vector immunity does not impede boosting of responses to M...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2013-09, Vol.31 (39), p.4247-4251
Hauptverfasser:	Cottingham, Matthew G, Carroll, Miles W
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Animals antigens cell-mediated immunity Genetic vaccine Genetic Vectors genetically modified organisms HIV Human immunodeficiency virus Humans Immunization Laboratories Malaria Medical research Modified vaccinia virus Ankara (MVA) Mycobacterium Neoplasms - therapy pathogens Poxvirus Public health Recombinant Smallpox Tuberculosis Vaccination Vaccine vaccine development Vaccines Vaccines, Attenuated Vaccines, DNA - adverse effects Vaccines, DNA - genetics Vaccines, DNA - immunology Vaccines, DNA - therapeutic use Vaccinia virus Vaccinia virus - genetics Vaccinia virus - immunology Vector Vector-borne diseases Viral Vaccines - adverse effects Viral Vaccines - genetics Viral Vaccines - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Recombinant MVA is most immunogenic as a heterologous boost after strong priming. • Most transgenes do not result in genetic instability of recombinant MVA. • Large-scale manufacturing of non-recombinant MVA is a reality. • Anti-vector immunity does not impede boosting of responses to MVA transgene product. • There is no convincing evidence of MVA replication in human cells.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2013.03.021